Revelation Biosciences, Inc. announced groundbreaking top-line activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint of the study, which evaluated the safety and tolerability of escalating doses of Gemini, was successfully met. This positive safety profile is a critical step for further development.
The study also demonstrated that Gemini normalized the inflammatory response at the cellular level in the treated CKD patients. This finding is highly significant as it provides direct evidence of Gemini's mechanism of action in a human patient population. The company believes these results could potentially revolutionize the treatment of acute and chronic inflammatory diseases.
Revelation Biosciences plans to host a corporate update webcast and conference call on September 10, 2025, to review these data in detail. These positive results are expected to support future development of the GEM-CKD, GEM-AKI, and GEM-PSI programs. The successful outcome of this Phase 1b study marks a major milestone for the company's lead candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.